Skip to content
value.today

Verenium Corp.

Formerly DIVERSA CORP, Industrial Genome Sciences, Inc., Industrial Biocatalysis, Inc.

Total raised
$21 M
2 rounds on record
Latest round
$7 M
Dec 2012
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Verenium Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2012$7 MNo. 2$2 to $10 million

Verenium Corp.: Raise no. 2, Dec 2012

Investors in this round

2 investors had bought by the notice of Dec 19, 2012: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander A Fitzpatrick · Executive Officer
  • James Levine · Executive Officer, Director
  • Janet Roemer · Executive Officer
  • Jeffrey A Black · Executive Officer
  • Cheryl F. Wenzinger · Director
  • Fernand F. Kaufman · Director
  • James H. Cavanaugh · Director
  • John F. Dee · Director
  • Joshua F. Ruch · Director
  • Michael F. Zak · Director
  • Peter F. Johnson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $7,309,564.32 which the Issuer may receive upon the exercise of certain warrants.”

Signed by Alexander A. Fitzpatrick, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Dec 19, 2012. Read the notice at the SEC.

optionsSEC
Sep 2009$14 MNo. 1$10 to $50 million

Verenium Corp.: Raise no. 1, Sep 2009

Investors in this round

8 investors had bought by the notice of Oct 2, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
$1,000
What was sold
equity, debt, other: Notes convertible into common stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos A. Riva · Executive Officer, Director
  • Gerald M. Haines · Executive Officer
  • Gregory B. Powers · Executive Officer
  • James B. Levine · Executive Officer
  • Janet B. Roemer · Executive Officer
  • Jeffrey G. Black · Executive Officer
  • John B. Howe · Executive Officer
  • Nell B. Jones · Executive Officer
  • William H. Baum · Executive Officer
  • Cheryl F. Wenzinger · Director
  • Fernand F. Kaufman · Director
  • James H. Cavanaugh · Director
  • John F. Dee · Director
  • Joshua F. Ruch · Director
  • Michael F. Zak · Director
  • Peter F. Johnson · Director
  • Simon F. Rich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Issuer exchanged $30,467,000 of 5.5% Convertible Senior Notes due 2027 for $13,707,000 of 9% Convertible Senior Notes due 2027.”

Signed by Gerald M. Haines II, Executive Vice President. Source: SEC Form D and 1 amendment, newest notice filed Oct 2, 2009. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Verenium Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2012).

    SEC Form D · Dec 2012

  • It delivers 1 product named in the sources below.

    See Products and services

  • The industry group it chose in its notices: Other Energy.

    SEC Form D · Dec 2012

Products#

1 named by the sources below.

  • enzyme

    Wikidata · Wikidata: product or material produced (P1056)

Services#

No services of Verenium Corp. are on record.

Investors#

No investor of Verenium Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Verenium Corp.
NameRoleNamed in
Alexander A FitzpatrickExecutive officerDec 2012
James LevineExecutive officerDec 2012
Janet RoemerExecutive officerDec 2012
Jeffrey A BlackExecutive officerDec 2012
Carlos A. RivaExecutive officerOct 2009
Gerald M. HainesExecutive officerOct 2009
Gregory B. PowersExecutive officerOct 2009
James B. LevineExecutive officerOct 2009
Janet B. RoemerExecutive officerOct 2009
Jeffrey G. BlackExecutive officerOct 2009
John B. HoweExecutive officerOct 2009
Nell B. JonesExecutive officerOct 2009
William H. BaumExecutive officerOct 2009
Gregory PowersExecutive officerSep 2009
Nell JonesExecutive officerSep 2009
Cheryl F. WenzingerDirectorDec 2012
Fernand F. KaufmanDirectorDec 2012
James H. CavanaughDirectorDec 2012
James LevineDirectorDec 2012
John F. DeeDirectorDec 2012
Joshua F. RuchDirectorDec 2012
Michael F. ZakDirectorDec 2012
Peter F. JohnsonDirectorDec 2012
Carlos A. RivaDirectorOct 2009
Simon F. RichDirectorOct 2009
Cheryl WenzingerDirectorSep 2009
Fernand KaufmannDirectorSep 2009
Joshua RuchDirectorSep 2009
Michael ZakDirectorSep 2009
Peter JohnsonDirectorSep 2009
Simon RichDirectorSep 2009

About

American industrial biotechnology company.